NEW YORK, Dec. 9, 2025 — Radial today announced the company has raised $50 million in venture funding to create access to the world’s most advanced mental health treatments. The company is backed by General Catalyst, who led the Series A, and additional investors Solari Capital, JSL Health Capital, Founder Collective, BoxGroup, Scrub Capital, and Diede van Lamoen.

New brain medicines – treatments like neuromodulation (e.g. accelerated transcranial magnetic stimulation, (TMS)) and rapid-acting medications (e.g. Spravato) that directly heal the brain – are achieving far better outcomes for patients with mental health conditions. These treatments work in days to weeks, with some studies showing remission rates as high as 78%. However, the current healthcare system is designed to deliver long-term medication-based management, not the more episodic interventional brain medicine supported by modern evidence. Further, the system does not measure outcomes, which limits payors ability to pay for the best care possible, and clinicians lack the best clinical decision support and operational tools to enable these new forms of care at scale.

Radial is addressing this problem for patients, providers, and payers by developing clinical infrastructure, reimbursement tools, and decision support that’s designed around modern brain medicine. The company is building a national network of clinics that accept most major forms of insurance, including Medicare, Tricare, VA-CCN, Aetna, Cigna, United, and many Blues plans. For patients, this means the most effective combination of therapies are available to everyone who needs them. For clinicians, this means focusing on providing that care. And, for payors, this means better outcomes and less ultimate cost for even the most complex patients.

John Capecelatro, CEO and co-founder of Radial, commented, “People who are struggling with mental health can’t wait years to see if something might help through trial and error. New rapid-acting treatments work in days or weeks instead of years. We’re seeing remission rates for depression of 50-60% and as high as 78% in some studies our team has co-authored. The healthcare system hasn’t caught up. Radial is here to change that. When we have tools for the right clinical workflows and insurance pathways, people can access therapies that help them get better far sooner. It’s a dramatic difference for individuals, for families, and for the health system that ends up carrying the cost when care drags on without results.”

Reva Nohria, Partner at General Catalyst, said, “Psychiatry is undergoing a transformation, but most of that progress hasn’t reached patients. The science is there, yet the infrastructure to deliver modern, brain-based treatments at scale is still missing. Radial understands both the clinical evidence and the operational complexity required to close that gap. We believe this work can meaningfully expand access to effective mental health care.”

Owen Muir, Chief Medical Officer at Radial, added, “In research, we’ve proven that these powerful treatments work. They change lives. The hard part has always been bringing them into everyday clinical practice. Radial was built to close that gap. We’re taking what we know from years of clinical research and turning it into care that any patient can access. Radial is focused on the care patients have long deserved.”

Radial currently operates with seven clinics in six states, supported by its proprietary software platform. This fundraising will support the company’s plans to expand nationally in 2026, growing both its clinic network and technology partnerships.

About Radial
Radial is expanding access to the world’s most advanced mental health treatments by Radial is developing clinical infrastructure, reimbursement tools, and AI-guided decision support designed around novel psychiatry treatments like neuromodulation (e.g. TMS), medication (e.g. Spravato), and other interventional therapies. Their goal is to make transformative brain medicine accessible to all. Learn more at www.meetradial.com.

Media Contact:
Jacquelyn Miller
‪415-745-1794
[email protected]

SOURCE Radial

PHOENIX, Dec. 9, 2025 — Cloverleaf Networks, a leading provider of next-generation connectivity, cybersecurity, and collaboration solutions for modern workforces, today announced a strategic venture capital investment from Super K Ventures, a prominent early-stage technology investor known for backing high-growth companies transforming the digital infrastructure landscape.

This investment marks a significant milestone in Cloverleaf Networks’ mission to deliver a more resilient, intelligent, and customer-centric approach to business connectivity. The new funding will accelerate product innovation across the company’s flagship offerings—including Cloverleaf Connect, Cloverleaf Anywhere, Cloverleaf SASE, and collaboration platform Ryver—while expanding market reach in the United States and abroad.

“Super K Ventures’ investment is a strong validation of our vision to modernize business connectivity and cybersecurity through simplicity, transparency, and an unmatched customer experience,” said Joe Faherty, Founder & CEO of Cloverleaf Networks. “This partnership positions us to scale faster, innovate deeper, and deliver even greater value to the organizations that rely on Cloverleaf every day.”

Super K Ventures brings deep expertise in scaling B2B infrastructure, SaaS, and cloud-native technology firms. Their support will help Cloverleaf Networks accelerate hiring in engineering, product development, and customer success, while also expanding its national footprint of managed service capabilities.

“Cloverleaf Networks is redefining how companies connect, protect, and manage their distributed workforce environments,” said Renee Klenert, Managing Partner at Super K Ventures. “The combination of their technology, customer-centric culture, and operational excellence represents exactly what we look for in a long-term partner.”

Cloverleaf Networks’ SaaS platform CLOE remains a core differentiator, providing centralized visibility, proactive monitoring, and simplified network management from a single intuitive interface. CLOE will expand its AI-driven analytics and automation capabilities, empowering IT teams to maintain network health and security in real time.

About Cloverleaf Networks

Cloverleaf Networks provides fully managed, secure, cloud-optimized connectivity solutions for remote, hybrid, and multi-site businesses. Headquartered in Phoenix, Arizona, Cloverleaf delivers internet, SD-WAN, cybersecurity, and collaboration services powered by its CLOE operations platform and backed by the Emerald Service Commitment.

About Super K Ventures

Super K Ventures is a venture capital firm focused on early-stage investments in high-growth technology companies. With an emphasis on digital infrastructure, enterprise software, and AI-driven platforms, Super K Ventures partners with visionary founders to accelerate innovation and scale transformative businesses.

SOURCE Cloverleaf Networks

Opine’s new funding, led by S3 Ventures, solves a decades-old problem for companies selling complex solutions, where selling and delivering their solutions requires detailed multi-department synchronization.

RALEIGH, N.C., Dec. 9, 2025 — Opine announced today that it has raised five million USD in new financing led by S3 Ventures of Austin, Texas, with participation from Knoll Ventures, Atlanta Seed Company, Gray Ventures, Propel Ventures, Triangle Tweener Fund, and Feross Aboukhadijeh, CEO of Socket.dev. This investment comes after Opine recorded 10x revenue growth in 2025, establishing itself as a rapidly growing market necessity. The capital will accelerate development of Opine’s unified AI-native workspace designed to streamline the entire technical sales cycle from initial discovery to post-sale delivery for complex B2B technology vendors.

Complex enterprise deals often span multiple departments, rely on an array of unconnected tools, and are hampered by siloed conversations. Solution engineers spend hours rebuilding context, leaders lack visibility into deal risks, and post-sales teams often inherit customers without knowing what was promised. Opine was created to fix this by bringing every team, data source, and process into a single intelligent workspace that surfaces risks early, automates repetitive work, captures every evaluation and handoff accurately, and keeps everyone aligned throughout the customer lifecycle.

“We’re excited to use this funding to continue to grow and support our innovative customers. They’re building and selling some of the most sophisticated B2B solutions available and need a unified AI-native system that understands their market and supports all the effort that goes into winning complex deals. This investment allows us to deepen our AI capabilities, advance our product, and expand our go-to-market reach,” said Akash Ganapathi, CEO and co-founder of Opine.

“We are thrilled to be backing the Opine team. After we spoke to executives at multiple customers, it became clear that Opine’s AI-native platform consistently makes sales, customer success, and product teams more effective at winning new business and delivering value,” said Eric Engineer, Partner at S3 Ventures.

“Since switching to Opine earlier this year, we’ve gained clearer opportunity insights, faster answers, and tighter team alignment, often cutting out a 30-minute call with a single question. We’re excited to expand our use of their playbooks and to see what the team builds next with their new funding,” said Mark Rida, Director of Solutions Engineering (Opine customer).

“The Opine team really understands the challenges of presales teams at scale. You can feel it in how they’ve built their product and with every interaction with their team. We’re happy to be able to deliver an excellent working experience to our prospects and customers,” shared Jaime Lewis-Gross, SVP, Sales Engineering (Opine customer).

Opine plans to use the capital to advance workflow automation, real-time deal intelligence, and unified data infrastructure. The company will also expand its market presence as technical sales becomes one of the most strategic functions in modern B2B organizations.

About Opine

Opine is an AI-native workspace built for technical sales teams, connecting presales to post-sales in one intelligent system. By automating workflows, surfacing real-time insights, and bringing every stakeholder together, Opine helps revenue-critical teams move faster, sell smarter, and deliver lossless customer handoffs. The platform replaces spreadsheets, tribal knowledge, and manual updates with a unified solution that reflects how technical sales actually operates. Founded in Raleigh, Opine is trusted by leading B2B companies to close complex deals with clarity and precision across an ever-increasingly complex and fast-moving world. Learn more about Opine at www.tryopine.com 

About S3 Ventures

Founded in 2005, S3 Ventures is one of the largest and longest-serving venture capital firms based in Texas, but investing nationwide. Backed by a philanthropic family with a multi-billion-dollar foundation, we empower visionary founders with the patient capital and true resources required to grow extraordinary, high-impact companies in Business Software and Healthcare Technology. With over $1B in assets under management, we lead Seed, Series A, and Series B rounds, with initial investments ranging from $500K to $15M and the capacity to invest $25M over the life of a company. Learn more at www.s3vc.com.

CONTACT: Nate Meadows; Head of Marketing, Opine; [email protected]

SOURCE Opine

SAN FRANCISCO, Dec. 9, 2025 — PhyxUp Health, an AI-driven Remote Therapeutic Monitoring (RTM) platform founded by a former physical therapist and Harvard graduate, is transforming how rehabilitation clinics operate throughout the United States. Built as a next-generation patient management and engagement solution, PhyxUp enables clinics to remotely monitor patient progress, increase therapy adherence, and streamline communication beyond the clinic walls. The platform incorporates automated documentation and integrated RTM billing, ensuring clean reimbursement workflows that help outpatient practices boost both patient outcomes and revenue while avoiding additional administrative burden.

Overcoming Structural Limitations in the Rehabilitation Market

Rehabilitation clinics, including physical therapy, occupational therapy, and speech therapy providers, face heavy administrative burdens that reduce the amount of time clinicians can dedicate to direct patient care. PhyxUp Health addresses this challenge through a unified workflow that enables clinics to remotely monitor and communicate with patients between visits while automating tasks such as billing, documentation, eligibility verification, and onboarding. By enhancing patient engagement and outcome tracking, PhyxUp equips therapists with real-time insights that support more informed clinical decisions between visits. The platform’s AI-driven analytics also help identify risk factors, assess adherence, and guide patients toward more efficient recovery pathways.

Technological Innovation in AI-Powered RTM 

PhyxUp Health delivers an end-to-end B2B SaaS platform that enables physical therapy practices to provide continuous, between-visit patient care while unlocking new reimbursement through RTM:

• AI-Driven Patient Monitoring: Automatically analyzes symptoms and exercise activity to catch issues early and alert providers when patients need attention.
• Automated Documentation & Billing: Automatically generates all RTM documentation and completes the full billing process for the clinic, minimizing administrative work.
• Fully Managed RTM Service: Licensed remote physical therapists handle patient monitoring and follow-ups for the clinic, delivering a hands-off RTM service.

Growing Adoption Across the United States

PhyxUp Health is experiencing rapid adoption as more clinics transition to digital-first and data-enabled patient care models. The platform is now utilized by independent private practices, multi-location clinic networks, and hospital-affiliated outpatient departments. Adoption by a Harvard Medical School-affiliated provider, along with collaboration with the Marcus Institute for Aging Research, validates PhyxUp Health’s clinical credibility and reinforces its trusted role within the evolving digital rehabilitation ecosystem.

Future Growth Strategy

Following its pre-seed investment in 2024, PhyxUp Health is preparing for a $1M seed raise to support the next stage of its U.S. growth. Over the coming year, the company plans to expand its RTM operations nationwide, enhance its partnerships with practice management systems, and build more advanced AI tools that help clinics anticipate patient outcomes and identify potential issues earlier. As more rehabilitation providers adopt technology to improve continuity of care, PhyxUp Health is emerging as an important infrastructure partner in the digital rehab market.

About PhyxUp Health

PhyxUp Health, founded by CEO Sangwon Lim, a former physical therapist and Harvard graduate, has emerged as one of the leading AI-powered Remote Therapeutic Monitoring (RTM) platforms in the U.S. The company supports physical therapy clinics and hospitals – including a Harvard Medical School affiliate – by providing a fully automated, end-to-end RTM service that includes patient monitoring, follow-ups, and billing. PhyxUp Health is currently raising a $1M seed round to accelerate product development and nationwide expansion.

For more information, visit https://phyxuphealth.com/

SOURCE PhyxUp Health

Funding from Khosla Ventures and SeaX Ventures follows FDA clearance and RSNA 2025 debut; company advances toward commercial deployment

BOSTON, Dec. 9, 2025 — a2z Radiology AI, developer of AI systems for comprehensive medical imaging interpretation, today announced a $4.5M seed round with participation from Khosla Ventures and SeaX Ventures. The funding will accelerate commercial deployment of the company’s FDA-cleared triage system and continued R&D toward broader imaging interpretation capabilities.

The investment comes on the heels of two milestones: FDA clearance for a2z-Unified-Triage, the first system to simultaneously triage seven urgent conditions on abdomen-pelvis CT scans in the U.S. market, and the company’s debut at RSNA 2025, where it presented the first prospective study evaluating AI-assisted preliminary report drafting for abdomen-pelvis CT.

That study demonstrated that AI assistance reduced reporting time by 17.8%, increased radiologist confidence by 14.8%, and decreased mental demand by 22.4%—while improving detection of findings without increasing false positives. The results offer early evidence that comprehensive AI can meaningfully improve both accuracy and efficiency, addressing longstanding questions about the real-world value of radiology AI.

“Radiology is one of the areas that will benefit the most from AI, ensuring no disease goes undetected,” said Vinod Khosla of Khosla Ventures. “While others focus on single conditions, a2z is able to evaluate imaging for a broad range of issues, bringing us closer to the comprehensive capabilities of a real-life radiologist.”

“Radiology is central to modern medicine, but delays can slow down care when timely answers are essential,” said Dr. Kid Parchariyanon, Founder and Managing Partner of SeaX Ventures. “a2z is meeting this challenge with technology that brings expert-level support directly to clinicians. We’re proud to support a2z as they build the tools that make a meaningful difference for providers and patients worldwide.”

With imaging demand outpacing the radiology workforce, clinicians face growing wait times for reads that guide critical decisions. Abdomen-pelvis CT alone accounts for over 20 million exams annually in the U.S.—the highest-volume CT category. a2z’s approach differs from existing AI solutions that address single conditions: the company is building toward systems that can evaluate imaging comprehensively, the way radiologists actually work.

“The response at RSNA validated what we’ve been building—AI that considers everything from A to Z in each study,” said Pranav Rajpurkar, PhD, co-founder of a2z Radiology AI and Associate Professor at Harvard Medical School. “This funding lets us keep pushing on R&D while bringing our cleared technology to the care teams who need it.”

“We’re building toward comprehensive interpretation of complex imaging studies at a level that simply hasn’t existed before,” said Samir Rajpurkar, co-founder and CEO.

The funding will support partnerships with health systems, continued product development, and commercial rollout in 2026.

About a2z Radiology AI

a2z Radiology AI is building the intelligence layer for medical imaging, making radiologist-level interpretation accessible on demand. The company develops AI systems that provide immediate answers to questions about CT scans, starting with comprehensive abdomen-pelvis analysis and expanding across imaging modalities and anatomies. Founded in 2024, a2z was co-founded by Pranav Rajpurkar, an Associate Professor at Harvard Medical School and pioneer in generalist medical AI, and Samir Rajpurkar, a technology industry veteran. a2z-Unified-Triage is FDA-cleared and available for clinical deployment.

For more information, visit https://a2zradiology.ai

About Khosla Ventures

Khosla Ventures is a venture capital firm focused on investments in artificial intelligence, financial services, healthcare, consumer, enterprise, and sustainability. It is known for making early capital investments in startups such as OpenAI, Guardant Health, Instacart, Affirm, DoorDash, and Block.

For more information, visit https://www.khoslaventures.com/

About SeaX Ventures

SeaX Ventures is a global venture capital firm dedicated to investing in deep-tech startups shaping the future through groundbreaking innovations. With a mission to empower entrepreneurs building exponential technologies, SeaX Ventures focuses on sectors with high potential to drive meaningful economic and environmental impact. SeaX leverages relationships with over 500 listed companies, multinationals, and major family businesses in Southeast Asia to support portfolio companies.

For more information, visit https://seaxventures.vc

Media Contact

[email protected]

SOURCE a2z Radiology AI

Oversubscribed round demonstrates strong investor confidence in Lin Health’s neuroscience-based approach to chronic pain

DENVER, Dec. 9, 2025 — Lin Health, the leader in behavioral care for chronic pain recovery, today announced the close of an oversubscribed $11 million Series A financing round. The round was led by Proofpoint Capital, a U.S.-based venture firm formed by seasoned healthcare operators, with participation from new investors Osage Venture Partners and NewHealth Ventures. Continued strong support and investment came from existing investors, including aMoon, Mayo Clinic, Saban Ventures, Shoni Health Ventures, and Viola Ventures.

In partnership with major health systems, clinics, and payers, Lin Health is redefining chronic pain care to treat conditions as diverse as migraines, irritable bowel syndrome (IBS), and back and joint pain. Accessible to more than 60 million covered Americans, Lin offers patients an effective, non-opioid treatment that addresses the root cause of pain in the nervous system. Through a physician-led, coach-supported virtual program, Lin engages patients multiple times per week as a high-touch resource grounded in decades of clinical research and aligned with national guidelines for chronic pain management.

“This milestone reflects the confidence of our investors and the urgency of addressing our growing chronic pain crisis, as at least one in five doctor visits are tied to pain,” said Lin Health CEO and Co-Founder Yehuda Kogan. “We’ve proven that our mission-driven team and model deliver results for patients, systems, and payers, and now we’re ready to compound our rapid growth, scale our partnerships, and bring relief to the millions of underserved Americans living with these conditions.”

The company operates with a proven collaborative care model, leveraging its technology and AI software to scale operations and support patients and clinicians efficiently without increasing administrative costs, while deepening integration across the healthcare ecosystem. The new funding will be used to drive product innovation, expand go-to-market efforts, strengthen clinically integrated partnerships, and accelerate Lin’s role as the first-line solution for chronic pain care nationwide.

“Lin Health has built a category-defining approach to chronic conditions as they tackle one of the most costly and overlooked challenges in U.S. healthcare: chronic pain,” said Dan Goldsmith of Proofpoint Capital, who joins Lin Health’s board. “Their model doesn’t just deliver meaningful outcomes for patients; it also addresses systemic inefficiencies and financial realities for payers and care teams. I’ve seen firsthand how the right combination of technology and clinical expertise can transform an industry, and Lin is poised to do just that for pain care. I’m excited to join the board and support the team in scaling this important mission.”

About Lin Health

Lin Health tackles the biggest blind spot in U.S. healthcare: chronic pain, which costs more than cancer and diabetes combined at $635 billion annually. Our evidence-based, award-winning treatment retrains maladaptive pain circuits and restores function, bridging medical and behavioral care through elements of Pain Reprocessing Therapy, Emotional Awareness and Expression Therapy, Cognitive Behavioral Therapy, and other neuroplastic pain recovery techniques. Our adjunctive care improves population health, reduces provider burnout, supports value-based outcomes, lowers the total cost of care, and prevents system leakage. Founded in 2021 by industry veterans and backed by leading investment firms, we partner with health systems, clinics, and payers to deliver immediately accessible continuity of care, built on end-to-end proprietary software that handles the entire business side of care delivery. With nationwide payer coverage for 60 million Americans, Lin is on a mission to reclaim lives from chronic pain.

Learn more at www.lin.health

Media Contact:

[email protected] 

SOURCE Lin Health

In addition, four seasoned B2B executives have joined the Invictus Guild as Operating Advisors: Stacey Epstein, Barry Zwarenstein, Nate Peace, and Gordon Mackintosh

SAN MATEO, Calif., Dec. 9, 2025 — Invictus Growth Partners (“Invictus”), a leading middle-market growth equity firm with more than $1 billion in assets under management, today announced that Erik Nierenberg has joined the firm as a Partner. Nierenberg will partner with current and future portfolio companies to accelerate growth and drive long-term value creation. Invictus also welcomed four senior executives to the Invictus Guild, its network of operating advisors, further expanding the firm’s value-creation capabilities across the portfolio.

2025 has been a transformative year for Invictus. The firm more than doubled AUM with new oversubscribed funds totaling $574 million dedicated exclusively to enterprise cloud software, cybersecurity, and financial technology companies seeking both capital and operating resources to scale.

“The pace of innovation in cloud software and applied AI continues to accelerate, creating massive opportunities for companies that can scale into market leaders,” said Erik Nierenberg. “I have worked with the Invictus team for years as part of the Invictus Guild and as a Board Director. Invictus combines deep operating and investing expertise with a unique data-science platform to help companies capture those opportunities. I’m excited to join the Invictus team and partner with companies to drive scale and growth.”

Nierenberg brings more than two decades of B2B software leadership across sales, marketing, product, strategy, operations, business development, and M&A. Most recently, he served as CEO of Litmus, where he led the company for eight years during which the company achieved significant scale by profitably growing direct sales at a 55% CAGR and growing EBITDA profitability at a 63% CAGR. Litmus evolved from a single-product, single-channel business into a multi-product enterprise platform trusted by leading global brands. Under his leadership, Litmus was successfully acquired by Validity in April, 2025.

“Erik is a world-class operator who has already driven transformational impact for our portfolio as part of the Invictus Guild,” said John DeLoche, Co-Founder and Managing Partner. “We’re thrilled to welcome him as a Partner to extend that value creation more broadly across the firm.”

Earlier in his career, Nierenberg held strategy, product, and go-to-market roles at Salesforce.com during its hyper-growth years. He also served as SVP and GM at Lynda.com (acquired by LinkedIn), was a consultant at Bain & Company, worked as an early-stage venture capitalist, and was part of the founding team at The Bridgespan Group. He has advised founders and CEOs at companies including 6sense, DataFox (acquired by Oracle), Udemy, Identified (acquired by Workday), and Bitly. At Invictus, he currently serves on the boards of Channelscaler and CYPHER Learning. Nierenberg holds a bachelor’s degree with honors in Economics from Pomona College and an MBA from Stanford Graduate School of Business.

“Erik shares our values and our mission to Empower Excellence,” added William Nettles, Co-Founder and Managing Partner. “His leadership has strengthened our value creation efforts, and we’re excited to have him on the full-time team.”

New Invictus Guild Operating Advisors

The Invictus Guild is a portfolio company success team of operating advisors that work closely with Invictus portfolio companies on value creation. Invictus also announced the addition of four new Invictus Guild operating advisors:

Stacey Epstein – Enterprise software veteran who helped build, scale, and exit iconic SaaS brands including SuccessFactors (from $10 million ARR to an IPO and subsequent acquisition by SAP for $3.4 billion), ServiceMax (less than $1M ARR to $1 billion acquisition by GE), Zinc (acquired), and Freshworks (IPO). She has served as CEO, CMO, Chief Customer Experience Officer, and Board Director.

Barry Zwarenstein – Seasoned finance leader who has guided technology companies through scaling, acquisitions, and IPOs, including Five9, Logitech, and Verifone. As longtime CFO of Five9, he helped grow the business from $60 million to over $1 billion in revenue; he brings strategic finance and capital-markets expertise to the Invictus portfolio.

Nate Peace – SaaS operator with deep expertise in customer success, operations, and post-sale growth. Currently SVP of Customer Success at LinkLive, he supports portfolio companies in retention, expansion, and operational excellence.

Gordon Mackintosh – Global go-to-market and channel leader who has built partner ecosystems at HPE, Juniper Networks, Cisco, and Extreme Networks. A CRN Channel Chief of the Year and Top 50 Most Influential Channel Chief, he helps accelerate revenue through world-class channel strategies.

Invictus Growth Partners is a middle-market growth equity firm with over $1 billion in assets under management, investing in bootstrapped and capital-efficient cloud software, cybersecurity, and fintech companies. The firm is deploying more than $574 million from recently closed funds and provides portfolio companies exclusive access to DIANE, its AI-driven value-creation platform, which has delivered a significant increase in direct sales conversion and can provide access to thousands of warm customer introductions. Invictus makes majority investments with $30 million to $100+ million equity checks. Visit us at www.invictusgrowth.com.

Contact: [email protected] 

SOURCE Invictus Growth Partners

With landmark demonstrations of quantum error correction and new backing from Google Quantum AI, NVIDIA, SoftBank, and other global investors, QuEra advances from scientific breakthroughs to preparing for industrial-scale deployment.

BOSTON, Dec. 9, 2025 — QuEra Computing, the leader in neutral-atom quantum computing, today highlighted 2025 as a defining year for QuEra and the quantum industry. In 2025, QuEra and its partners at Harvard, MIT, and Yale resolved the fundamental barriers to fault-tolerant quantum computing, demonstrating continuous operation, scalable error correction, magic state distillation, and dramatically reduced runtime overhead. Simultaneously, the company secured over $230 million in capital from top-tier investors and major industry partners to expand globally, complete development initiatives and scale manufacturing. QuEra also achieved record revenues and cash collections from customers for quantum computing product and service deliveries, marking its transition from research organization to commercial enterprise. By uniting these scientific breakthroughs with the company’s first on-premises HPC quantum computer deployment, QuEra has established 2025 as the year fault tolerance moved from theoretical promise to engineering reality.

“2025 marked a turning point, where the foundational science behind our market-leading neutral atom quantum computing matured into a clear and validated path forward,” said Andy Ory, CEO of QuEra Computing. “Working closely with our partners at Harvard and MIT, we collectively validated the entire architectural blueprint for a large-scale, error-corrected quantum computer. With backing from the world’s leaders in AI and compute, and our first systems live in hybrid HPC environments, QuEra is now executing on the quickest and most credible path to quantum utility.”

Scientific Validation: The Blueprint for Scale
Four landmark papers published in Nature this year have resolved the critical engineering risks facing neutral-atom quantum scaling. Unlike superconducting or trapped-ion approaches that increasingly struggle with cryogenic cooling, wiring, connectivity, or control complexity as they scale, QuEra’s neutral-atom platform has now demonstrated the unique physical capabilities required for massive scale:

• Solving the Scale Barrier (Continuous Operation): This is the first demonstration of a quantum system that can replenish qubits indefinitely, enabling continuous operation at scale. In a breakthrough led by Harvard and MIT, researchers demonstrated a 3,000-qubit array operating continuously for over two hours, utilizing unique mid-computation replenishment to solve the “atom loss” problem. (Nature)
• Solving the Error Barrier (Fault Tolerance): This architecture validates that increasing the system size now reduces errors rather than multiplying them. The Harvard-led team demonstrated the first integrated fault-tolerant architecture, successfully executing algorithms with up to 96 logical qubits with error rates that improved as the system scaled (below-threshold performance). (Nature)
• Solving the Utility Barrier (Magic States): This proves that neutral atoms can efficiently prepare the high-fidelity resources needed for complex, universal algorithms. Led by QuEra scientists, the team achieved the first logical magic state distillation, a prerequisite for running universal, complex algorithms beyond simple proofs of concept. (Nature)
• Solving the Overhead Barrier (Algorithmic Fault Tolerance): This framework dramatically reduces the runtime cost of error correction, enabling fault-tolerant algorithms to execute 10-100× faster. In collaboration with Harvard and Yale, researchers introduced Transversal Algorithmic Fault Tolerance (AFT), proving that each logical layer of an algorithm can be executed with a single error-checking round rather than dozens. (Nature)

The Neutral-Atom Advantage

QuEra’s rapid progress is driven by the unique architecture of its neutral-atom platform. Unlike manufactured qubits that are fixed in place and require individual wiring, neutral atoms are identical by nature, controlled wirelessly by lasers, and highly mobile. This mobility enables the dynamic rearrangement of qubits for efficient algorithms and novel error correction techniques. Uniquely, QuEra systems support room-temperature operation and low power consumption, enabling a compact, energy-efficient footprint.

Delivering Immediate Scientific Impact

Beyond laying the foundation for future fault tolerance, QuEra’s platforms are generating breakthrough science today. In June, researchers from the University of Innsbruck and Harvard used QuEra’s Aquila system to observe string breaking in a 2D quantum simulator for the first time—a phenomenon central to high-energy particle physics (Nature). In September, a Harvard-QuEra-MIT collaboration published the first digital quantum simulation of two-dimensional fermionic systems using Kitaev’s honeycomb model, verifying a non-Abelian spin-liquid phase and simulating the Fermi-Hubbard model on a square lattice. This opens pathways for quantum simulations in materials science, chemistry, and high-energy physics (Nature). This result headlines a broader wave of discovery, with dozens of papers published by scientific users leveraging QuEra’s systems via the cloud to explore frontiers in physics, machine learning, and optimization.

Industrialization: Validated by Leaders in AI and Compute
Following these technical validations, the broader computing industry has moved to integrate QuEra’s technology into the global supply chain.

• Capital for Manufacturing Scale: QuEra closed more than $230 million in new financing round led by Google Quantum AI and SoftBank Vision Fund 2, with an additional strategic investment from NVentures (NVIDIA), and other global investors. This capital accelerates the manufacturing infrastructure and supply chain required to deliver systems globally. Further, QuEra doubled its global workforce this year, with additional significant growth planned for 2026.
• Global Manufacturing Infrastructure: Complementing this capital, QuEra was selected for Japan’s NEDO “Post-5G” initiative, a multi-year national project to establish a robust manufacturing supply chain for quantum components. This partnership secures the critical optical and vacuum technologies needed to mass-produce neutral-atom systems for the global market.
• Hybrid Compute Reality: QuEra completed its first on-premises installation at AIST (Japan), where its Gemini-class system now operates alongside the NVIDIA-powered ABCI-Q supercomputer. Further validating this hybrid future, QuEra and Dell Technologies showcased the integration of QPUs into mainstream HPC environments at SC25.
• Enterprise Readiness: The expansion of the “go to market” QuEra Quantum Alliance to include BCG X, a partnership with Deloitte Japan, alongside impactful results with partners like Merck and Amgen, signals that the enterprise sector is preparing for utility-scale applications. Additionally, QuEra’s advancement to Phase 2 of the Wellcome Leap Quantum for Bio Challenge demonstrates the platform’s growing relevance for life sciences applications.
• Government Validation: As previously announced, QuEra was selected for Phase B of DARPA’s Quantum Benchmarking Initiative, following success in Phase A.

Strategic Implications for the Industry
These milestones materially reduce the risk profile for HPC centers, national laboratories, and enterprise early adopters:

• For HPC Centers: The successful integration with Dell and NVIDIA infrastructure proves that neutral-atom QPUs can function as standard accelerators within existing data centers today.
• For National Programs: The company’s selection for DARPA’s Quantum Benchmarking Initiative (Stage A, and then Stage B), combined with the demonstration of logical qubits, provides a verified roadmap to utility. These de-risk long-term investments in sovereign quantum capabilities, a strategy further validated by NEDO’s supply chain investment with QuEra in Japan.
• For Enterprise Innovators: The path to fault-tolerant quantum computing is now primarily an engineering execution task, not a scientific uncertainty, bringing deep circuit applications in materials and logistics within sight.

Looking Ahead
Leveraging the architectural validations of 2025, QuEra is on track to demonstrate its third-generation systems in 2026-2027. These systems are designed to feature a large number of high-quality logical qubits operating continuously, unlocking new solutions for classically-intractable problems and cementing QuEra’s position as the standard-bearer for fault-tolerant quantum computing.

With these breakthroughs, QuEra now offers the clearest, most validated roadmap to delivering fault-tolerant quantum computers capable of running deep logical circuits—positioning the company as the industry’s technical and commercial leader entering 2026.

QuEra will host a technology update webinar in early 2026. To be informed of the event details, register your interest here: www.quera.com/26roadmap

About QuEra Computing
QuEra is putting quantum to work. As the scientific and commercial leader in neutral-atom quantum computing, we help enterprise innovators leverage quantum to gain competitive advantage, support HPC centers as they help users tackle classically intractable problems, and enable government programs to build national capability and sovereign capabilities. We do this through our quantum innovation platform, combining quantum systems available on-premises and via the cloud with application co-design and collaborative research. Born at Harvard and MIT, still advancing together, QuEra operates globally from Boston, Tokyo, and the United Kingdom. As quantum computing moves from “one day” to “Day One,” QuEra delivers practical impact today while advancing toward large-scale, fault-tolerant systems. See what’s possible at www.quera.com. 

Media Contact: [email protected]

SOURCE QuEra Computing

The round was led by Upfront Ventures, with participation from BlueYard Capital, First In Ventures, and other strategic investors.

The funding enables AnySignal to scale manufacturing across a growing portfolio of software and hardware products, including flight radios currently in orbit and next-generation systems for ground and airborne use.

Modern life depends on reliable access to the radio-frequency spectrum, yet many defense and space operators still rely on brittle, single-purpose radios. These legacy systems often fail under congestion, interference, or evolving threats, creating unacceptable risks for satellite communications and national security.

“Failing radios and operational communications breakdowns are less about physics and more about inflexible designs and rigid processes,” said John Malsbury, AnySignal co-founder and CEO. “As more satellites, missiles and drones come online, the weaknesses of existing infrastructure become clear. Without modernization, missions and lives are put at risk and we won’t meet the growing demands of the space economy and defense readiness.”

AnySignal’s platform makes spectrum a software-defined resource. By designing the full radio stack –  from algorithms and hardware to cloud services –  the company said it can deliver new capabilities in weeks rather than years, and allow systems to adapt to attacks without replacing hardware.

“The commercial world has seen huge advances in communications infrastructure, while defense and space have lagged behind,” said Ricardo Medina, AnySignal co-founder. “We’re modernizing the core building blocks so mission-critical users can finally outpace the threat.”

AnySignal is already supporting multiple missions on-orbit, the company said. Over the next year, 12 additional spacecraft are scheduled to launch using AnySignal radios and network services across LEO, GEO and lunar missions.

“Every founder we talk to in space knows AnySignal and sees it as one of the best solutions available,” said Mark Suster, general partner at Upfront Ventures. “Backing this team was a no-brainer.”

About AnySignal
AnySignal builds mission-critical space and national security infrastructure. We deliver adaptive, resilient wireless connectivity, sensing, and security infrastructure through full-stack solutions that combine advanced algorithms, ruggedized hardware, and cloud services. Our platform is trusted by space, defense, and commercial customers to operate reliably in the most demanding environments.

Media Contact
Email: [email protected]
Phone: (310) 880-3433
Website: https://www.anysignal.com/ 
LinkedIn: https://www.linkedin.com/company/anysignal

SOURCE AnySignal